Patent AU-2018396877-A1 (AU)
Title: Anti-LAG3 antibody and uses thereof
Inventor: MIAO XIAONIU
IPC: A61P35/00
Filed: 2018-12-27
Abstract: (12) J fd* -9JW1NFFIL IN -E P il$ (1019)l (43) d VTWO 2019/129137 A1 2019 4 7 P 4 (04.07.2019) WIPO I PCT (51) M p']-414 : [CN/CN]; +P 3 [ N T f I L N E C07K 16/28 (2006.01) C12P 21/02 (2006.01) TW168, Jiangsu 215123 (CN)o A61K39/395 (2006.01) A 61P 3100 (2006.01) A61P35/00 (2006.01) GOiN 33/68 (2006.01) (72)&flRX:t 'i-MIAO,Xiaoniu); + 41 C12N 15/13 (2006.01) IT )i H I 1 I i EX 3T 168 , Jiangsu 215123 (CN)0 1tH (HU, Huajing); + [4I (21p PCT/CN2018/124315 I )+ [ [I +1 H R X 3T 168 (22) MI8i H: 2018 4 12 n 27 H (27.12.2018) Jiangsu215123 (CN)o It- $(TSUN, Andy); li T I W IT ) r IT & A T R ¶ X 3T, 168 (25) $ Jiangsu215123 (CN) o 'J2lW (LIU,Junjian); (26): +l I & 3 A if IT 1 I N X 3T, H S 168 (30) vItyf Z, Jiangsu 215123 (CN)o Al0'J%**(LIU,Xiaolin); 201711449486.7 2017*12f]27H (27.12.2017) CN + 4 I)H&i )H1 kH2 X3'F 201811561512.X 2018*12A 19 H (19.12.2018) CN 168t, Jiangsu 215123 (CN)o (71) $LA : : " f $I] jR (-3, 1,1f ) ;h PR 15 (INNOVENT BIOLOGICS (SUZHOU) CO., LTD.) (54) Title: ANTI-LAG-3 ANTIBODY AND USES THEREOF (54)&fl $: ri LAG-3IMt74 f)j HEK293-LAG-3 AA 15000- -4- ADI-26789 AA HEK293-LAG-3 Cell Bonding Experiment -+- ADI-26869 BB Mean Fluorescence Intensity [MFI] 1000 -- 25F7 CC Antibody Concentration (nM) 4 5000 ADI-26789 12.137 AD-26869 2.909 0.01 01 1 10 1(0 1000 CC AINVf)! ("M) (57) Abstract: The present invention relates to new-type antibodies and antibody fragments that specifically bind to LAG-3 and com positions containing the antibodies or antibody fragments. Furthermore, the present invention relates to nucleic acids encoding the antibodies or antibody fragments thereof, and host cells comprising the antibodies or antibody fragments thereof, and related uses. enlFurthermore, the present invention relates to the therapeutic and diagnostic uses of these antibodies and antibody fragments. In partic ular, the present invention relates to therapy combining these antibodies and antibody fragments with other therapeutic agents, such e as anti-PD-i or anti-PD-L I antibodies. (57)O ~k t tG- H rHfft& 4 it1ffi 0 t3 tk t3A itf no t4M itQ fltyF aHAWi nhiiPD-1&P D-Ll rt Y rt rXn + PJ1_hAntS W O 2019/129137 A 1 ||||11111|||||||||||||||I|11|1|DI|I|I|II |||||DI |I|||||||||||||||||||||||||| (74) tI:L', I t@$||||Mf(ZHONGZILAW OFFICE); t 01L 17lT)Z£¶%7Jt]26 iftitM'h7)2, Beijing 100034 (CN) AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZWc Mfi)): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), kil (AM, AZ, BY, KG, KZ, RU, TJ, TM), KIXI (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). - [IFT*It (*j9M21*(3))